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cense.Abstract Aim of the work: To evaluate the uterine–umbilical artery Doppler velocimetry and
determine its relation to pregnancy outcome and disease manifestations in SLE patients.
Patients and methods: Blood ﬂow velocity waveforms of the umbilical and uterine arteries were
studied by color Doppler ultrasound in 36 pregnant SLE patients referred from the Rheumatology
Department for follow up and delivery in the Obstetrics Department. Resistance index (RI) and
pulsality index (PI) were measured at the 1st week and then every 4 weeks from the 20th and
30th weeks till delivery.
Results: The mean age was 27.33 ± 4.03 years and disease duration of 5.72 ± 2.57 years. The
nulliparity rate and history of previous abortions were higher in those with poor fetal outcome
(50% and 62.5%, respectively). Lupus anticoagulants and anticardiolipin were obviously higher
in those with a poor outcome (25% and 37.5%, respectively) with a higher association with APS
in spite of anticoagulation. The SLEDAI was higher in those with a poor fetal outcome and the
difference reached signiﬁcance at the 24th week gestation (12.13). Eight (22.22%) of the patients
had abnormal fetal outcome: 5 IUGR (13.89%), 1 IUFD (2.78%) and 2 (5.55%) with missed abor-
tion. Uterine and umbilical artery Doppler abnormalities were higher in those with poor obstetric
outcomes and were earlier revealed by the uterine.0101811162.
(S.M. Gamal).
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188 T.A. Gheita et al.Conclusion: Uterine artery Doppler seems to be an earlier prognostic factor for adverse out-
comes compared to umbilical in SLE patients at high risk, allowing antepartum intensive care
and optimal timing of delivery to early conﬁrm a good pregnancy outcome.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Systemic lupus erythematosus (SLE) is a multi-system autoim-
mune connective tissue disorder that primarily affects women
of childbearing age. Pregnancy outcomes in women with
SLE have signiﬁcantly improved though a poor outcome is
increased at least twofold compared with the normal popula-
tion [1]. Pregnancy in SLE patients can be a concern, placing
the mother and fetus at risk [2]. Most rheumatic diseases that
are well controlled prior to pregnancy do not deteriorate in
pregnancy, providing that the patient continues with appropri-
ate disease-modifying therapy [3]. Patients with rheumatic dis-
eases who become pregnant are justiﬁably categorized as
having high-risk pregnancies. Utilizing a multidisciplinary
approach successful pregnancies have become the rule rather
than the exception. However, women with rheumatic disease
are particularly prone to develop serious obstetric problems
[4].
The most frequently observed autoimmune rheumatic dis-
ease during pregnancy is SLE where the immunoendocrine
changes may inﬂuence its course [5]. Particular interest must
be paid to the impact of SLE and its therapies on pregnancy
and, conversely, the effect of pregnancy on the disease, which
may have long-lasting implications for mothers and fetuses [6].
Adverse fetal outcomes, maternal disease ﬂares, and drug
potential teratogenic risk are the main reasons why pregnant
SLE patients are considered a high-risk population [7].
The obstetric management of the pregnant SLE patients is
largely dictated by the degree to which it is associated with ad-
verse obstetric outcomes, maternal or fetal. A co-ordinated
management effort on the part of obstetricians and rheumatol-
ogists will likely yield the optimal achievable results [8]. Intra-
uterine growth retardation (IUGR) is more likely in patients
with active systemic disease, hypertension, a history of throm-
bosis and renal involvement [3]. Serial Doppler studies preg-
nant SLE patients showed that the absence of end-diastolic
frequencies in the umbilical artery was a good predictor of
the need for subsequent delivery by caesarian section [9].
Repeated Doppler umbilical artery velocimetry has been
reported to be an effective way to follow pregnancies associ-
ated with APS and to indicate the timing of premature deliv-
ery. Color Doppler evaluation of the uterine artery RI was a
good tool for early identiﬁcation of pregnancies at major risk
of having earlier delivery and lower birth weight and birth per-
centile. It provided a reliable method of studying blood ﬂow in
the uteroplacental circulation and strongly suggested impaired
trophoblastic invasion of the placental bed, before any clinical
sign of pre-eclampsia or IUGR [10]. Uterine artery Doppler
velocimetry provides a non-invasive method to study the uter-
oplacental blood ﬂow and impaired placental perfusion and is
a useful tool to identify antiphospholipid syndrome (APS)
pregnancies at higher risk of poor outcome [11]. Abnormal
resistance index of the uterine arteries at 18–24 weeks’ gesta-tion predicted pregnancies at major risk for obstetric complica-
tions [10].
The aim of the present work was to determine fetal and
maternal outcomes in pregnant SLE patients and detect the
relation to disease manifestations, investigations and activity.
2. Patients and methods
2.1. Study population
Thirty-six pregnant SLE patients with a mean age of 27.33 ±
4.03 years, fulﬁlling the updated American College of Rheu-
matology (ACR) revised criteria for the classiﬁcation of SLE
[12] were recruited from the Rheumatology Department and
outpatient clinic of Cairo University Hospitals during the year
2009. They were followed up till delivery in the Obstetrics
Department.
Full history taking, thorough clinical examination and lab-
oratory investigations were performed for all the patients and
their current drug therapy was also reported. Disease activity
and damage were assessed using the SLEDAI [13] and
SLICC/ACR DI [14], respectively. An informed consent was
obtained from all patients. CBC, ESR, liver and kidney func-
tion test in addition to C3 and C4 were measured. The ANA,
anti-double-stranded DNA, Anti-Ro and Anti-La as well as
anticardiolipin antibodies (IgG and IgM) were determined.
Blood ﬂow velocity waveforms of the umbilical and uterine
arteries were studied by color Doppler ultrasound. Resistance
index (RI) and pulsality index (PI) were measured at the ﬁrst
week and then every 4 weeks from the 20th and 30th week till
delivery.
Ultrasound assessment of uterine artery Doppler velocime-
try was performed by Accuvix machine (Medison, Seoul,
Korea) using 3.5–5 MHz trans-abdominal probe and with
interrogation of the main uterine artery at crossing with the
iliac vessels. Doppler indices were taken (RI and PI). Both uter-
ine arteries velocimetry were taken and the average indices were
calculated. Umbilical artery velocimetry assessment was done
using the same machine and the RI was measured in a free-
ﬂoating loop of the umbilical cord neither close to the placenta
nor to the fetal abdomen during periods of fetal inactivity.
Random site for the umbilical artery was determined and the
Doppler indices were taken (PI, RI). The 95th percentile for
gestational age was used as the cutoff for abnormality. The
study conforms to the ethics and standards currently applied
in Cairo University Teaching Hospitals.
Statistical analysis, Statistical Package for Social Science
(SPSS) program version 15 was used for analysis of data. Data
was presented as mean ± SD. Mann–Whitney test was used
for analysis of two quantitative data. One way ANOVA was
used to compare more than two quantitative data. Pearson’s
correlation was used for detection of the relation between
two variables. p-Value was considered signiﬁcant if <0.05.
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The study included 36 pregnant SLE patients with a mean age
of 27.33 ± 4.03 years and disease duration of 5.72 ± 2.57
years. A quarter of the patients were nullipara being more in
those with poor outcome (50%) compared to those with nor-
mal outcome (17.9%). Half of the patients had history of a
previous abortion with a tendency to being higher in those
with a poor outcome. Clinical manifestations are shown in
Table 1. There was no signiﬁcant difference between the pa-
tients with a normal or poor outcome as regards the age and
disease duration. Those with poor fetal outcome had a signif-
icantly less mean offspring number (p 0.016) and there was a
tendency for higher history of abortions in these patients.
The disease activity (SLEDAI) and damage index (SLICC)
increased throughout pregnancy. The mean SLEDAI at the
ﬁrst week was 7.53 ± 2.31 and reached 8.6 ± 3.08 at the
24th week. Similarly, the SLICC was 0.61 ± 0.9 and became
0.78 ± 0.93. There was a higher SLEDAI and SLICC in those
with a poor outcome and the difference reached signiﬁcance
for the disease activity at the 24th week (12.13 ± 3.27 and
7.57 ± 2.18, respectively, p 0.005).
The laboratory investigations of the studied SLE patients at
the beginning of pregnancy were as follows: erythrocyte
sedimentation rate (ESR) (63.5 ± 25.34 mm/1st hour), hemo-
globin (Hb) (10.12 ± 1.01 g/dl), white blood cells (WBCs)
(7.32 ± 3.29 · 103 mm3), platelets (230.4 ± 64.1 · 103
mm3), aspartate transaminase (AST) (25.44 ± 17.1 U/l),
alanine transaminase (ALT) (37.9 ± 85.01 U/l), albumin
(3.8 ± 0.49 g/dl), proteinuria 0.8 ± 0.95 g/24 h), creatinine
(0.67 ± 0.34 mg/dl), Complement C3 (87.8 ± 25.7 g/l), C4
(16.75 ± 7.7 g/l). The antinuclear antibody (ANA) was posi-
tive in all patients, anti-dsDNA in 26 (72.2%) and the anticar-
diolipin (IgG and IgM) were positive in 10 (27.78%). There
was no signiﬁcant difference between the studied laboratory
investigations of those with a poor and normal outcome. How-
ever, two patients with a poor outcome had positive lupus anti-
coagulants and another had positive Anti-Ro/Anti-La. The
associated APS was more evident in those with a poor out-
come in spite of adequate anticoagulation throughout preg-
nancy. All the patients were receiving steroids with a mean
dose of 14.72 ± 7.14 mg/day; azathioprine was received byTable 1 Clinical manifestations of the pregnant SLE patients.
Clinical manifestations, number (%) All patients (36)
Mucocutaneous 28 (77.78)
Nephritis 15 (41.67)
Arthritis 24 (66.67)
Serositis 10 (27.78)
Hematological 10 (27.78)
Raynaud’s 4 (11.11)
Neuropsychiatric 3 (8.33)
Myositis 3 (8.33)
IPF 3 (8.33)
APS 4 (11.11)
AVN (hip) 2 (5.55)
SLS 1 (2.78)
Hypertension 2 (5.55)
IPF: Interstitial pulmonary ﬁbrosis; APS: anti-phospholipid syndrome; A25 patients (100 mg/day) and hydroxychloroquine (HCQ)
(400 mg/day) by 15.
Eight (22.22%) of the patients had abnormal fetal outcome:
5 with IUGR (13.89%) (one of them gave preterm labor at 34th
week), 1 IUFD (2.78%) and 2 (5.55%) with missed abortion.
All other patients (77.77%) delivered full-term and the fetuses
were of good health and none had neonatal lupus. In the pres-
ent study, two patients had pregnancy induced hypertension.
Complement was consumed in one and the other had possible
pre-eclampsia (2.78%) and the fetal outcome was good in both.
Two patients with abnormal indices delivered by caesarian sec-
tion, otherwise, all others had a normal vaginal delivery. The
Doppler uterine and umbilical RI and PI in the studied patients
according to the outcome are presented in Tables 2 and 3 and
graphically presented in Fig. 1. Fig. 2 shows the abnormal uter-
ine and umbilical arteries Doppler velocimetry.
The umbilical resistance index (RI) was signiﬁcantly higher
than the uterine through-out pregnancy. The difference
became insigniﬁcant at the 40th week. Moreover, the umbilical
pulsality index (PI) was higher than the uterine. However, the
difference reached signiﬁcance during the 1st, 28th, 30th and
38th weeks. During the ﬁrst week, the uterine RI and PI were
initially high. They were higher than the 95th percentile with
notching, throughout pregnancy till delivery, in 8 patients.
Starting from the 24th week, uterine RI and PI were signiﬁ-
cantly higher in those with poor fetal outcomes. Umbilical
RI and PI were signiﬁcantly higher in those with poor outcome
starting from the 30th week till full term.
The uterine and umbilical RI and PI did not show a consid-
erable correlation with the age or disease duration. The uterine
RI signiﬁcantly negatively correlated with the platelets, C3 and
SLICC (R 0.44, p 0.008; R0.38, p 0.02 and R0.4, p 0.015,
respectively) at the 1st week gestation and with the serum albu-
min at the 20th week (R 0.41, p 0.014). A signiﬁcant positive
correlation was present with the SLEDAI at the 24th week
(R 0.34, p 0.04). The umbilical RI signiﬁcantly negatively cor-
related with the steroid dose at the ﬁrst and 30th week of ges-
tation at (R 0.54, p 0.001 and R 0.4, p 0.017, respectively),
with the C4 at the 40th week (R 0.51, p 0.002) and with
SLICC at the 1st week (R 0.38, p 0.02).
The uterine PI at the 38th week signiﬁcantly negatively cor-
related with the WBC count (R 0.4, p 0.015). Umbilical PIPoor outcome (8) Normal outcome (28)
6 (75) 22 (78.6)
5 (62.5) 10 (35.7)
5 (62.5) 19 (35.7)
3 (37.5) 7 (25)
3 (37.5) 7 (25)
0 (0) 4 (14.3)
1 (12.5) 2 (7.1)
0 (0) 3 (10.7)
0 (0) 3 (10.7)
3 (37.5) 1 (3.6)
0 (0) 2 (7.1)
0 (0) 1 (3.6)
0 (0) 2 (7.1)
VN: avascular necrosis; SLS: shrinking lung syndrome.
Figure 1 Uterine and umbilical Doppler velocimetry; pulsality index (PI) and resistance index (RI) in SLE patients.
Table 3 Doppler umbilical resistance (RI) and pulsality (PI) index throughout pregnancy in SLE patients.
Umbilical Doppler (mean ± SD) Resistance index (RI) Pulsality index (PI)
Pregnancy outcome
Poor (8) Normal (28) p Poor (8) Normal (28) p
First week 0.89 ± 0.08 0.88 ± 0.11 0.68 1.28 ± 0.3 1.31 ± 0.29 0.82
Week 20 0.77 ± 0.05 0.78 ± 0.06 0.54 1.50 ± 0.5 1.45 ± 0.48 0.8
Week 24 0.63 ± 0.26 0.70 ± 0.04 0.47 0.93 ± 0.4 1.03 ± 0.21 0.54
Week 28 0.73 ± 0.04 0.70 ± 0.04 0.06 1.06 ± 0.18 1.01 ± 0.2 0.48
Week 30 0.71 ± 0.05 0.66 ± 0.04 0.018 1.22 ± 0.26 0.98 ± 0.09 0.03
Week 34 0.68 ± 0.08 0.60 ± 0.07 0.039 1.12 ± 0.22 0.89 ± 0.15 0.025
Week 38 0.70 ± 0.1 0.61 ± 0.05 0.034 1.04 ± 0.16 0.88 ± 0.08 0.029
Week 40 0.66 ± 0.13 0.53 ± 0.05 0.02 1.05 ± 0.27 0.71 ± 0.06 0.009
p value 0.002 0.000 0.016 0.000
Table 2 Doppler uterine resistance (RI) and pulsality (PI) index throughout pregnancy in SLE patients.
Uterine Doppler (mean ± SD) Resistance index (RI) Pulsality index (PI)
Pregnancy outcome
Poor (8) Normal (28) p Poor (8) Normal (28) p
First week 0.75 ± 0.07 0.70 ± 0.13 0.22 1.41 ± 0.54 1.23 ± 0.54 0.41
Week 20 0.64 ± 0.12 0.65 ± 0.04 0.81 1.22 ± 0.56 1.07 ± 0.19 0.48
Week 24 0.70 ± 0.12 0.53 ± 0.04 0.004 1.47 ± 0.79 0.79 ± 0.09 0.046
Week 28 0.64 ± 0.1 0.54 ± 0.05 0.02 1.01 ± 0.26 0.85 ± 0.1 0.13
Week 30 0.58 ± 0.06 0.49 ± 0.12 0.014 0.96 ± 0.21 0.75 ± 0.24 0.03
Week 34 0.61 ± 0.04 0.59 ± 0.1 0.49 0.95 ± 0.1 0.89 ± 0.22 0.29
Week 38 0.54 ± 0.07 0.47 ± 0.05 0.03 0.73 ± 0.12 0.61 ± 0.07 0.025
Week 40 0.56 ± 0.09 0.54 ± 0.1 0.74 0.91 ± 0.21 0.75 ± 0.14 0.08
p value 0.000 0.000 0.045 0.000
190 T.A. Gheita et al.signiﬁcantly negatively correlated with the platelets at the 24th
and 40th weeks gestation (R 0.38, p 0.02 and R0.34, p 0.04,
respectively). A signiﬁcant correlation was present with the
ESR at the 1st week (R 0.39, p 0.02) and negatively with the
hemoglobin level at 40th week (R 0.34, p 0.04). There was
no other signiﬁcance between the RI or PI with all the other
studied laboratory parameters.4. Discussion
Recent data demonstrated that advances in the management of
pregnant patients with autoimmune diseases have improved
the prognosis for mother and child. However, these patients
are still classiﬁed as high risk because of the potential for ma-
Figure 2 Abnormal uterine (left) and umbilical (right) artery color Doppler velocimetry with uterine notching.
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22.22% of patients: 5 with IUGR (13.89%) and one of them
gave preterm labor at 34th week, 1 IUFD (2.78%) and 2
(5.55%) with missed abortion. This was comparable to the re-
sults of another study that found women with rheumatologic
diseases at increased risk of adverse obstetric outcomes and
IUGR (8%) [16]. A recent study detected the fetal outcome
of pregnant SLE patients to be stillbirth (7.1%), IUGR
(14.3%), and pre-term delivery rates (23.1%) [17]. Further-
more, a signiﬁcant risk of IUGR (28.5%) was present in preg-
nant SLE patients [18].
Pre-eclampsia was possibly present in (2.78%) and the fetal
outcome was good which may be due to the proper manage-
ment. Women with rheumatologic diseases were more likely
to have pre-eclampsia [16]. However, in a similar study, the
pre-eclampsia rate was 2.4% in pregnant SLE patients [17].
In the study of Roncoglia et al. [19], it was concluded that
the later in pregnancy the abnormal uterine artery Doppler
ﬁndings are observed, the greater the risk of pre-eclampsia.
Normalization of uterine artery Doppler after 25 weeks
reduces the risk of pre-eclampsia. In the normal population,
poor outcomes are much less found as pre-eclampsia occured
in 1.2% and IUGR in 1.1% of 6035 pregnancies [20].
In this study, the skin and joints were more frequently
affected (77.78% and 66.67%, respectively) and the renal
involvement was 41.67%, being higher in those with a poor fe-
tal outcome (62.5%). This is in agreement with the study of
Ambro´sio et al. [21], but the renal affection was only 14%.
Antiphospholipid syndrome (APS) was present in 4 patients,
3 of them had a poor fetal outcome. Similarly, lupus anticoag-
ulants (LA) and anticardiolipin (ACL) antibodies were obvi-
ously higher in those with a poor outcome (25% and 37.5%,
respectively). In a similar study, LA and ACL IgG and IgM
antibodies were present in 33%, 16.6% and 19%, respectively,
of pregnant SLE patients but without any signiﬁcant inﬂuence
on poor obstetric outcome [17]. It was reported that prematu-
rity and IUGR are common in SLE, but are not associated
with APS [22]. Moreover, SLE patients with APS had a worseobstetric history, with no other signiﬁcant differences in peri-
natal and obstetric outcome [23]. In the current study there
was no signiﬁcant correlation of the Doppler studies with the
ACL and LA. Similarly, a poor correlation was found between
antiphospholipid antibodies and Doppler results in pregnant
SLE patients [24]. The RI was signiﬁcantly lower in hyperten-
sive pregnant APS patients with ACL treated with aspirin and
low dose corticosteroids suggesting their beneﬁcial effect on
uterine perfusion [10]. In the present study, the SLEDAI
became signiﬁcantly higher starting from the 24th week gesta-
tion in those with a poor fetal outcome. In agreement with our
results is the study of Gayed and Gordon [3] who found that
IUGR is more likely in active systemic rheumatic disease
patients.
In the current study, the number of live births was good
(91.67%), still births (2.78%), no therapeutic abortions or
perinatal deaths, premature delivery (2.78%), IUGR (7.9%)
and only one patient had positive Anti-Ro/Anti-la antibodies
and did not have neonatal lupus or any congenital anomalies.
In a related study [25] the live births of SLE patients was less
favorable (60.1%), stillbirths (2.2%), therapeutic abortions
(14%), premature delivery (24.4%), IUGR (13.89%), neonatal
lupus (3.5%) and congenital anomalies (2.3%). It is notable
that 15 of the present SLE patients were receiving HCQ. In
SLE mothers with Anti-Ro/Anti-La antibodies, exposure to
HCQ during pregnancy may decrease the risk of fetal develop-
ment of cardiac-neonatal lupus [26]. Anti-Ro antibody does
not negatively inﬂuence the pregnancy outcome of SLE [27].
The SLEDAI was higher in those with a poor fetal outcome
and the difference reached signiﬁcance at the 24th week gesta-
tion to reach 12.13 (p 0.005). The pregnancy outcomes in SLE
were related to disease activity during conception [28]. Disease
ﬂare during pregnancy consistently affects the outcome as pre-
mature labor and IUGR were more commonly found [30]. In
the current study, a signiﬁcant positive correlation was present
between uterine RI and SLEDAI at the 24th week (R 0.34,
p 0.04). In a similar study, all the patients with abnormal
Doppler studies had SLE ﬂare-ups [24]. Maternal renal disease
192 T.A. Gheita et al.was the only statistically signiﬁcant predictor for fetal loss [25].
Active lupus nephritis during pregnancy is associated with a
higher incidence of maternal and fetal complications [29].
However, in a recent study renal involvement did not have
any signiﬁcant inﬂuence on poor obstetric outcome [17].
The umbilical RI and PI were obviously higher than the uter-
ine through-out pregnancy. During the ﬁrst week, the Uterine
RI and PI were initially high. They were higher than the 95th
percentile with notching, throughout pregnancy till delivery,
in 8 patients (22.22%). In agreement with this is the study that
showed that uterine Doppler PI and notching obtained during
the ﬁrst trimester are signiﬁcantly higher than those of the sec-
ond in pregnant women with normal outcomes [31]. Starting
from the 24th week gestation (uterine RI and PI) and from the
30th week onwards (umbilical RI and PI) were signiﬁcantly
higher in those with poor fetal outcomes. This may imply that
uterine Doppler abnormalities are early predictor of adverse
events before the umbilical. In agreement is the study that
showed that including uterine artery Doppler might detect a
group of pregnancies at high risk, even when the umbilical is
normal [32]. Patients had the poorest outcome when a reduced
ﬂow velocity was noted in both uterine–
umbilical vessels [24]. Cases with uterine artery Doppler abnor-
malities had signiﬁcantly poorer obstetric outcomes [17,33].
Furthermore, abnormal umbilical artery ﬂow velocity in preg-
nant SLE patients showed an increased risk of complications
[34]. In the present study, Doppler velocimetry is suggested in
pregnant SLE patients starting from the 24th week gestation.
In another study, a single 20 weeks uterine Doppler assessment
was recommended to detect pregnantwomenwith a high risk for
early-onset adverse outcomes [20]. An early observation (18–
24 weeks) of the uterine RI would detect the relationship be-
tween an abnormal RI and adverse pregnancy outcome [10].
In the present study, longitudinal assessment of the Doppler
ﬁndings suggested a trend toward reduction of the RI in preg-
nancies with an initial abnormal RI, similar to that observed
in healthy pregnant women although at higher levels. This is
in agreementwith the study ofCaruso et al. [10], as the reduction
could be due to the beneﬁcial effect of the treatment.
Uterine Doppler is a useful test in predicting high risk preg-
nancies secondary to uteroplacental insufﬁciency [35].
Although no present method to overcome IUGR exists, umbil-
ical velocimetry is expected to assist clinicians in predicting
perinatal outcome and also formulating antenatal surveillance
guidelines for such conditions [36]. Although pregnancy out-
come in SLE is improving, it is still a concern. However,
new strategies with respect to pregnancy timing and multidis-
ciplinary care have improved maternal and fetal outcome in
SLE [2,17]. Uterine artery Doppler seems to be a good prog-
nostic factor for adverse obstetric outcomes [17].
It could be concluded that pregnancies in SLE are associ-
ated with important maternal and fetal morbidities. The ideal
patients for pregnancy are those whose disease has been quies-
cent for several months before. A multidisciplinary manage-
ment of pregnant SLE patients and the cooperation of the
team players including the Obstetrician and Rheumatologist
are central. Non-invasive color Doppler of the umbilical and
uterine arteries during the late second and third trimesters
can allow identiﬁcation of at-risk pregnancies, allowing ante-
partum intensive care and optimal timing of delivery to early
conﬁrm a good pregnancy outcome and reduce the cost ofprenatal care in SLE. Further study using a larger number of
patients is recommended.
Conﬂicts of interest
The authors declare no conﬂicts of interest.
References
[1] Smyth A, Garovic VD. Systemic lupus erythematosus and
pregnancy. Minerva Urol Nefrol 2009;61:457–74.
[2] Yan-Yuen S, Krizova A, Ouimet JM, et al. Pregnancy outcome in
systemic lupus erythematosus (SLE) is improving: results from a
case control study and literature review. Open Rheumatol J
2008;2:89–98.
[3] Gayed M, Gordon C. Pregnancy and rheumatic diseases.
Rheumatology (Oxford) 2007;46:1634–40.
[4] Dudley DJ, Branch DW. Pregnancy in the patient with rheumatic
disease: the obstetrician’s perspective. Baillieres Clin Rheumatol
1990;4:141–56.
[5] Doria A, Iaccarino L, Ghirardello A, Arienti S, Zampieri S,
Rampudda ME, et al. Rare autoimmune rheumatic illnesses
during pregnancy. Systemic sclerosis, polymyositis/dermatomyo-
sitis and vasculitis. Z Rheumatol 2006;65:200–8.
[6] Motta M, Tincani A, Lojacono A, Faden D, Gorla R, Airo` P,
et al. Neonatal outcome in patients with rheumatic disease.
Lupus 2004;13:718–23.
[7] Mecacci F, Pieralli A, Bianchi B, Paidas MJ, et al. The impact of
autoimmune disorders and adverse pregnancy outcome. Semin
Perinatol 2007;31:223–6.
[8] Branch DW. Pregnancy in patients with rheumatic diseases:
obstetric management and monitoring. Lupus 2004;13:696–8.
[9] Kerslake S, Morton KE, Versi E, Buchanan NM, Khamashta M,
Baguley E, et al. Early Doppler studies in lupus pregnancy. Am J
Reprod Immunol 1992;28:172–5.
[10] Caruso A, De Carolis S, Ferrazzani S, Valesini G, Caforio L,
Mancuso S, et al. Pregnancy outcome in relation to uterine artery
ﬂow velocity waveforms and clinical characteristics in women with
antiphospholipid syndrome. Obstet Gynecol 1993;82:970–7.
[11] De Carolis S, Botta A, Santucci S, Garofalo S, Martino C, Perrelli
A, et al. Predictors of pregnancy outcome in antiphospholipid
syndrome: a review. Clin Rev Allergy Immunol 2010;8:116–24.
[12] Hochberg MC. Updating the American College of Rheumatology
revised criteria for the classiﬁcation of systemic lupus erythema-
tosus [letter]. Arthritis Rheum 1997;40:1725.
[13] Bombardier C, Gladman D, Urowitz M, Caron D, Chang CH,
et al. Derivation of the SLEDAI. A disease activity index for
lupus patients. The committee on prognosis studies in SLE.
Arthritis Rheum 1992;35:630–40.
[14] Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz
M, et al. The development and initial validation of the Systemic
Lupus International Collaborating Clinics/American College of
Rheumatology damage index for systemic lupus erythematosus.
Arthritis Rheum 1996;39:363–9.
[15] Borchers AT, Naguwa SM, Keen CL, Gershwin ME. The
implications of autoimmunity and pregnancy. J Autoimmun
2010;34J:287–99.
[16] Wolfberg AJ, Lee-Parritz A, Peller AJ, Lieberman ES. Associa-
tion of rheumatologic disease with preeclampsia. Obstet Gynecol
2004;103:1190–3.
[17] Madazli R, Bulut B, Erenel H, Gezer A, Guralp O. Systemic lupus
erythematosus and pregnancy. J Obstet Gynaecol
2010;30(1):17–20.
[18] Chen CY, Chen YH, Lin HC, Chen SF, Lin HC. Increased risk of
adverse pregnancy outcomes for hospitalisation of women with
Uterine–umbilical artery Doppler velocimetry and pregnancy outcome in SLE patients 193lupus during pregnancy: a nationwide population-based study.
Clin Exp Rheumatol 2010;28:49–55.
[19] Roncoglia N, Crippa I, Locatelli A, Cameroni I, Orsenigo F,
Vergani P, et al. Prediction of superimposed preeclampsia using
uterine artery Doppler velocimetry in women with chronic
hypertension. Prenat Diagn 2008;28:710–4.
[20] Llurba E, Carreras E, Grataco´s E, Juan M, Astor J, Vives A,
et al. Maternal history and uterine artery Doppler in the
assessment of risk for development of early- and late-onset
preeclampsia and intrauterine growth restriction. Obstet Gynecol
Int 2009:275613.
[21] Ambro´sio P, Lermann R, Cordeiro A, Borges A, Nogueira I,
Serrano F. Lupus and pregnancy––15 years of experience in a
tertiary center. Clin Rev Allergy Immunol 2010;38:77–81.
[22] Julkunen H, Jouhikainen T, Kaaja R, Leirisalo-Repo M,
Stephansson E, Palosuo T, et al. Fetal outcome in lupus
pregnancy: a retrospective case-control study of 242 pregnancies
in 112 patients. Lupus 1993;2:125–31.
[23] Cordeiro A, Lermann R, Ambro´sio P, Nogueira I, Serrano F.
Pregnancy and antiphospholipid antibodies in systemic lupus
erithematosus patients: an outcome evaluation. Acta Reumatol
Port 2009;34:486–91.
[24] Guzman E, Schulman H, Bracero L, Rochelson B, Farmakides G,
Coury A. Uterine–umbilical artery Doppler velocimetry in
pregnant women with systemic lupus erythematosus. J Ultrasound
Med 1992;11:275–81.
[25] Rahman P, Gladman DD, Urowitz MB. Clinical predictors of
fetal outcome in systemic lupus erythematosus. J Rheumatol
1998;25:1526–30.
[26] Izmirly PM, Kim MY, Llanos C, Le PU, Guerra MM, Askanase
AD, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La
antibody-associated cardiac manifestations of neonatal lupus in
fetuses of mothers with systemic lupus erythematosus exposed to
hydroxychloroquine. Ann Rheum Dis 2010;69:1827–30.
[27] Mavragani CP, Dafni UG, Tzioufas AG, Moutsopoulos HM.
Pregnancy outcome and anti-Ro/SSA in autoimmune diseases: a
retrospective cohort study. Br J Rheumatol 1998;37:740–5.[28] Alekberova ZS, Kosheleva NM, Belitskaia SG, Marichik NV.
Monitoring the activity of systemic lupus erythematosus in
pregnancy. Ter Arkh 1994;66:46–51.
[29] Foocharoen C, Nanagara R, Salang L, Suwannaroj S, Mahakka-
nukrauh A. Pregnancy and disease outcome in patients with
systemic lupus erythematosus (SLE): a study at Srinagarind
Hospital. J Med Assoc Thai 2009;92:167–74.
[30] Wagner SJ, Craici I, Reed D, Norby S, Bailey K, Wiste HJ, et al.
Maternal and foetal outcomes in pregnant patients with active
lupus nephritis. Lupus 2009;18:342–7.
[31] Liao AW, Toyama J, Costa V, Ramos C, Brizot M, Zugaib M.
Correlation between the Doppler velocimetry ﬁndings of the
uterine arteries during the ﬁrst and second trimesters of preg-
nancy. Rev Assoc Med Bras 2009;55:197–200.
[32] Ghosh GS, Gudmundsson S. Uterine and umbilical artery
Doppler are comparable in predicting perinatal outcome of
growth-restricted fetuses. BJOG 2009;116:424–30.
[33] Boukerrou M, Bresson S, Collinet P, Delelis A, Deruelle P,
Houfﬂin-Debarge V, et al. Factors associated with uterine artery
Doppler anomalies in patients with preeclampsia. Hypertens Preg
2009;28:178–89.
[34] Farine D, Granovsky-Grisaru S, Ryan G, Seaward PG, Teoh TG,
Laskin C, et al. Umbilical artery blood ﬂow velocity in pregnan-
cies complicated by systemic lupus erythematosus. J Clin Ultra-
sound 1998;26:379–82.
[35] Park Y. Is uterine artery Doppler velocimetry effective for
prediction of pre-eclampsia and intrauterine growth restriction?
[Editorial]. J Womens Med 2009;2:1–2.
[36] Byun YJ, Kim H, Yang JI, Kim JH, Kim HY, Chang SJ.
Umbilical artery Doppler study as a predictive marker of perinatal
outcome in preterm small for gestational age infants. Yonsei Med
J 2009;50:39–44.
